Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$7.48
-$0.01(-3.06%)
At close: 4:00 PM EST
$7.48
-$0.01(-3.06%)
Day’s Range― - ―
52-Week Range$0.52 - $8.00
Previous CloseN/A
Volume447.03K
Average Volume (3M)1.28M
Market Cap
$701.72M
Enterprise Value$474.23M
Total Cash (Recent Filing)$233.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding104,890,220
10 Day Avg. Volume1,853,010
30 Day Avg. Volume1,275,380
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.05
Forecast
1Y Price Target
$14.33Price Target Upside91.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 Efficacy For NDV‑01Durable, high complete-response rates and no progressions in Phase 2 materially de‑risk the core program. Sustained efficacy and clean safety improve the probability of a successful registrational outcome, strengthen the commercial value proposition, and anchor long-term strategic planning and partnerships.
Regulatory Alignment & Clear Phase 3 PathFormal FDA alignment and a defined two-pathway registrational design reduce regulatory uncertainty and speed development decisions. Clear endpoints, planned IND/timelines, and structured enrollment assumptions improve execution visibility and the odds of an efficient approval pathway if Phase 3 replicates Phase 2 results.
Strengthened Cash Runway And Debt-free Balance SheetA large financing and a debt-free capital structure materially extend runway and lessen near-term funding pressure. With multi-year cash visibility to complete pivotal studies, management can focus on execution and trial enrollment rather than immediate capital raises, improving strategic optionality.
Bears Say
Pre-revenue Profile With Persistent Cash BurnNo product revenues and recurring negative operating and free cash flows mean long-term value depends entirely on trial success and external financing. Persistent burn increases dependency on capital markets, heightens dilution risk, and leaves operational continuity contingent on successful execution of clinical milestones.
Rising G&A And Wider Absolute Net LossSteep increases in G&A reflect higher fixed operating costs as the company scales, which sustainably raises the cash burn baseline absent revenue. Combined with larger absolute losses, higher overhead narrows optionality and increases the magnitude of funding needed to reach commercialization or breakeven.
Dilution Risk From Share Authorization And Financing RelianceAn expanded share authorization and recent large private placement underscore ongoing reliance on equity to fund operations. Structural dependence on dilutionary financing can erode long-term shareholder value and signals that future capital raises remain a likely tool to bridge development-to-commercial milestones.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.52 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $701.72M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 42 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.02.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 104,890,220 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went up 0.537%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (91.62% Upside)
$14.33 (91.62% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
894.05%
12-Months-Change
Fundamentals
Return on Equity
-71.22%
Trailing 12-Months
Asset Growth
750.32%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: robust phase 2 12-month efficacy and safety data for NDV-01, FDA alignment for a two-pathway Phase 3 registrational program, strengthened IP positioning via a provisional patent filing, and a materially improved balance sheet with ~$234M cash (runway into 2029). Operational advantages (office-based, short administration) and a planned Cipranolone proof-of-concept add to the upside. Key challenges include a significant rise in G&A expense, a modestly larger absolute net loss, patent prosecution uncertainty, and potential variability in Phase 3 patient populations which could affect measured efficacy. Overall, the highlights substantially outweigh the lowlights, but successful execution of the planned mid-2026 trial starts and subsequent enrollment/readouts remain critical.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$14.33
▲(91.62% Upside)
Technical Analysis
Ownership Overview
2.87% Insiders
3.74% Mutual Funds
47.67% Other Institutional Investors
41.03% Public Companies and
Individual Investors